TNF Pharmaceuticals Operating Income 2012-2024 | TNFA

TNF Pharmaceuticals operating income from 2012 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.

TNF Pharmaceuticals Operating Income 2012-2024 | TNFA

TNF Pharmaceuticals operating income from 2012 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$82.4B
Takeda Pharmaceutical (TAK)$44.4B
Astellas Pharma (ALPMY)$21.1B
Sandoz Group AG (SDZNY)$19.8B
United Therapeutics (UTHR)$16.7B
Summit Therapeutics (SMMT)$14B
Shionogi (SGIOY)$12.7B
Neurocrine Biosciences (NBIX)$12.4B
Catalent (CTLT)$10.7B
Madrigal Pharmaceuticals (MDGL)$6.9B
Orion OYJ (ORINY)$6.8B
Jazz Pharmaceuticals (JAZZ)$6.8B
Ionis Pharmaceuticals (IONS)$5.7B
Corcept Therapeutics (CORT)$5B
Crinetics Pharmaceuticals (CRNX)$4.5B
PTC Therapeutics (PTCT)$3.1B
Dyne Therapeutics (DYN)$2.9B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
Arrowhead Pharmaceuticals (ARWR)$2.4B
Soleno Therapeutics (SLNO)$2.2B
Recursion Pharmaceuticals (RXRX)$1.8B
Centessa Pharmaceuticals (CNTA)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.7B
Ocular Therapeutix (OCUL)$1.6B
Harrow (HROW)$1.6B
NewAmsterdam Pharma (NAMS)$1.6B
Xencor (XNCR)$1.5B
ARS Pharmaceuticals (SPRY)$1.5B
Avadel Pharmaceuticals (AVDL)$1.4B